Payment overview · 2025
General Payments
$491.50
26 reported records · 11 companies
Healthcare provider profile · identity verified
Michael S Cole, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT SMITH, AR · NPI 1710973649
Verified facts
What the public records show
CMS Open Payments records show Michael S Cole, MD received $491.50 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $220.93 | 45.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.66 | 14.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.63 | 9.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.84 | 6.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.57 | 5.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.94 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.95 | 3.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.41 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.21 | 3.1% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.75 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.61 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $491.50 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $132.14 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.63 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $118.62 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.63 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 67 |
| Losartan Potassium | Losartan Potassium | 272 | 70 |
| Omeprazole | Omeprazole | 265 | 61 |
| Alprazolam | Alprazolam | 252 | 39 |
| Levothyroxine Sodium | Levothyroxine Sodium | 239 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 47 |
| Tramadol Hcl | Tramadol Hcl | 185 | 28 |
| Gabapentin | Gabapentin | 170 | 41 |
| Furosemide | Furosemide | 144 | 45 |
| Meloxicam | Meloxicam | 134 | 36 |
| Topiramate | Topiramate | 128 | 21 |
| Lisinopril | Lisinopril | 126 | 34 |
| Potassium Chloride | Potassium Chloride | 123 | 37 |
| Trazodone Hcl | Trazodone Hcl | 122 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 29 |
| Metformin Hcl | Metformin Hcl | 110 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 22 |
| Glipizide | Glipizide | 100 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 20 |
| Baclofen | Baclofen | 84 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 20 |
| Ozempic | Semaglutide | 82 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 17 |
| Clonazepam | Clonazepam | 69 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 15 |
| Atenolol | Atenolol | 65 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 17 |
| Ezetimibe | Ezetimibe | 64 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 14 |
| Carvedilol | Carvedilol | 61 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 15 |
| Finasteride | Finasteride | 61 | 15 |
| Sertraline Hcl | Sertraline Hcl | 60 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 24 |
| Diazepam | Diazepam | 54 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 16 |
| Fenofibrate | Fenofibrate | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 53 | 17 |
| Spironolactone | Spironolactone | 52 | 14 |
| Allopurinol | Allopurinol | 51 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 12 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Estradiol | Estradiol | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 20 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 20 |
| Famotidine | Famotidine | 29 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 19 |
| Azithromycin | Azithromycin | 26 | 21 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $491.50 · 26 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, PROQUAD, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXNEUVANCE, XIFAXAN, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error